n innovative nasal spray that has shown clinical effectiveness against respiratory viruses has been authorized for the Canadian market. The product, developed by the Viennese biotech company Marinome Biotechnologie GmbH, reduces the reproduction and spread of viruses on the nasal mucosa and is based on Marinomed’s proprietary technology platform Mavirex®, which employs polymers derived from red seaweed. This platform further enables the development of therapies for over 200 different respiratory virus strains.
Marinomed announced the Canadian approval of its antiviral nasal spray following the validation of convincing pre-clinical and clinical data on the safety and effectiveness of the drug. The product is based on the polymer Carragelose®, a natural substance extracted from red algae, and is now approved for the prevention and treatment of the common cold in 38 countries throughout the world. Thanks to its good tolerability, it is also available without a prescription for children starting from the age of one, as well as for pregnant women and breastfeeding mothers.
The polymer surrounds the viruses and thereby prevents them from attaching to and entering the cells in the nasal mucosa. At the same time, it forms a beneficial and protective layer of moisture in the nose. Clinical studies prove that treatment with the nasal spray reduces the duration of a viral cold by around two days (compared with patients treated with placebos). In addition, the viral load and recurrences of the illness were reduced.
Commenting on the company’s latest market approval, Dr. Andreas Grassauer, CEO of Marinomed, said: “…our antiviral technology platform and our corporate strategy… are now focused on the development and approval of other products for the prevention and treatment of influenza and combined products for allergy sufferers.”